Article info

Rationale for azithromycin in COVID-19: an overview of existing evidence

Authors

  • Iwein Gyselinck Respiratory Diseases, KU Leuven University Hospitals, Leuven, Flanders, BelgiumDepartment CHROMETA - Research group BREATHE, KU Leuven, Leuven, Flanders, Belgium PubMed articlesGoogle scholar articles
  • Wim Janssens Respiratory Diseases, KU Leuven University Hospitals, Leuven, Flanders, BelgiumDepartment CHROMETA - Research group BREATHE, KU Leuven, Leuven, Flanders, Belgium PubMed articlesGoogle scholar articles
  • Peter Verhamme Cardiovascular Diseases, KU Leuven University Hospitals, Leuven, Flanders, BelgiumCentre for Molecular and Vascular Biology, KU Leuven, Leuven, Flanders, Belgium PubMed articlesGoogle scholar articles
  • Robin Vos Respiratory Diseases, KU Leuven University Hospitals, Leuven, Flanders, BelgiumDepartment CHROMETA - Research group BREATHE, KU Leuven, Leuven, Flanders, Belgium PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Iwein Gyselinck; iwein.gyselinck{at}kuleuven.be
View Full Text

Citation

Gyselinck I, Janssens W, Verhamme P, et al
Rationale for azithromycin in COVID-19: an overview of existing evidence

Publication history

  • Received October 20, 2020
  • Revised November 27, 2020
  • Accepted November 30, 2020
  • First published January 13, 2021.
Online issue publication 
January 13, 2021
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.